Mizuho Initiates Coverage On Belite Bio with Neutral Rating, Announces Price Target of $105
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
Mizuho analyst Graig Suvannavejh initiates coverage on Belite Bio (NASDAQ:BLTE) with a Neutral rating and announces Price Target of $105.
Mizuho analyst Graig Suvannavejh initiates coverage on Belite Bio (NASDAQ:BLTE) with a Neutral rating and announces Price Target of $105.